VJHemOnc is committed to improving our service to you

BSH 2019 | Ublituximab, umbralisib and ibrutinib in CLL and NHL

VJHemOnc is committed to improving our service to you

Loretta Nastoupil

The combination of ublituximab, umbralisib and ibrutinib was investigated in an open-label, Phase I dose escalation and expansion trial in chronic lymphocytic leukemia or R/R B-cell non-Hodgkin lymphoma (NCT02006485). We spoke to Loretta Nastoupil, MD, MD Anderson Cancer Center, Houston, TX, about the results seen with this chemo-free triplet regimen. This interview took place at the British Society for Haematology (BSH) 2019 Annual Meeting, held in Glasgow, UK.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter